摘要
目的观察重组组织型纤溶酶原激活剂(rt-PA)超早期静脉溶栓治疗急性脑梗死的临床效果。方法随机将我院2017年1月—2018年1月收治的86例急性脑梗死患者分两组,每组43例。对照组行常规治疗,观察组行rt-PA治疗。比较两组临床疗效。结果观察组总有效率、NIHSS评分以及ADL评分等指标均明显优于对照组(P <0.05)。结论重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死效果理想。
Objective To observe the clinical effect of recombinant tissue plasminogen activator(rt-PA)in the treatment of acute cerebral infarction with ultra-early intravenous thrombolysis.Methods 86 patients with acute cerebral infarction admitted to our hospital from January 2017 to January 2018 were randomly divided into two groups,43 in each group.The control group was given routine treatment and the observation group was given rt-PA treatment.The clinical efficacy of the two groups was compared.Results The total effective rate,NIHSS score and ADL score of the observation group were significantly better than the control group(P<0.05).Conclusion Recombinant tissue plasminogen activator is an effective method for the treatment of acute cerebral infarction.
作者
夏晓慧
XIA Xiaohui(Neurology Department,The First People's Hospital of Mudanjiang City,Mudanjiang Heilongjiang 157011,China)
出处
《中国卫生标准管理》
2018年第23期81-83,共3页
China Health Standard Management
